Study #2024-1486
A phase 2 platform study of novel combination therapies in participants with head and neck squamous cell carcinoma. sub study title: VELOCITY-HNSCC Substudy-01: A phase 2 study of novel combination therapies in participants with previously untreated recurrent or metastatic head and neck squamous cell carcinoma regardless of PD-L1 expression status.
MD Anderson Study Status
Enrolling
Treatment Agent
Domvanalimab, Zimberelimab, Paclitaxel, Carboplatin
Description
Master protocol: The main goal of this master clinical study is to evaluate the efficacy and safety of multiple novel combination therapies in participants with head and neck squamous cell carcinoma (HNSCC) in various substudies. Substudy-01 will evaluate the efficacy and safety of novel combination of treatment regimens, domvanalimab (DOM) and zimberelimab (ZIM) combined with chemotherapy vs ZIM combined with chemotherapy. The primary objective is to assess the efficacy of DOM and ZIM in combination with chemotherapy versus ZIM in combination with chemotherapy.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Head and Neck Squamous Cell Carcinoma
Study phase:
Phase II
Physician name:
Faye Johnson
Department:
Thoracic/Head & Neck Medical Oncology
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.